12 October 2023 
EMA/CHMP/445199/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Rubraca 
rucaparib 
On 12 October 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Rubraca. The marketing authorisation holder for this medicinal product is pharmaand GmbH. 
The CHMP adopted a new indication for Rubraca.  
For information, the full indications for Rubraca will be as follows2: 
Rubraca is indicated as monotherapy for the maintenance treatment of adult patients 
with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, 
or primary peritoneal cancer who are in response (complete or partial) following 
completion of first-line platinum-based chemotherapy. 
Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with 
platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal 
cancer who are in response (complete or partial) to platinum-based chemotherapy. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
